Abstract
The use of local ablative therapy to treat NSCLC with oligometastatic disease (metastatic disease present in a limited number of sites) and oligoprogressive disease (disease progression in a limited number of sites) has been explored in multiple small prospective and retrospective series. Both Gomez et al 2016 and Iyengar et al 2017 have shown the benefit of radiation therapy as consolidative therapy for oligometastatic disease treated with chemotherapy or targeted therapy. For oligoprogressive disease, numerous retrospective studies indicate a benefit with the use of local ablative therapies in patients receiving targeted therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
